1 New awakenings: current understanding of sleep dysfunction and its treatment in Parkinson's disease.

2 Telemonitoring Parkinson's disease using machine learning by combining tremor and voice analysis.

3 GRP78/BIP/HSPA5 as a Therapeutic Target in Models of Parkinson’s Disease: A Mini Review

4 The Swallowing Clinical Assessment Score in Parkinson’s Disease (SCAS-PD) Is a Valid and Low-Cost Tool for Evaluation of Dysphagia: A Gold-Standard Comparison Study

5 Changes of Retina Are Not Involved in the Genesis of Visual Hallucinations in Parkinson’s Disease

6 Biomechanical System Versus Observational Rating Scale for Parkinson’s Disease Tremor Assessment

7 Quality of life in Parkinson’s disease patients: progression markers of mild to moderate stages

8 Translational methods to detect asymmetries in temporal and spatial walking metrics in parkinsonian mouse models and human subjects with Parkinson’s disease

9 Metabolomic Profiling of Bile Acids in an Experimental Model of Prodromal Parkinson’s Disease

10 Effectiveness of SaeboReJoyce in the Evaluation of the Improvement of the Occupational Performance in Parkinson’s Disease: An Outcome Research

11 Psychological Benefits of Nonpharmacological Methods Aimed for Improving Balance in Parkinson’s Disease: A Systematic Review

12 Changes in Phonation and Their Relations with Progress of Parkinson’s Disease

13 Centenary of Tretiakoff’s thesis on the morphology of Parkinson’s disease, evolved on the grounds of encephalitis lethargica pathology

14 Long noncoding RNA HAGLROS regulates apoptosis and autophagy in Parkinson’s disease via regulating miR-100/ATG10 axis and PI3K/Akt/mTOR pathway activation

15 Identifying a glucose metabolic brain pattern in an adeno-associated viral vector based rat model for Parkinson’s disease using <sup>18</sup>F-FDG PET imaging

16 Classification of Patients with Parkinson’s Disease Using Medical Imaging and Artificial Intelligence Algorithms

17 A Cross-Sectional Study on Socioeconomic Systems Supporting Outpatients With Parkinson’s Disease in Japan

18 Clinical-Pharmacogenetic Predictive Models for Time to Occurrence of Levodopa Related Motor Complications in Parkinson’s Disease

19 Detection of orthostatic hypotension with ambulatory blood pressure monitoring in parkinson’s disease

20 Effects of acute cannabidiol administration on anxiety and tremors induced by a Simulated Public Speaking Test in patients with Parkinson’s disease

21 Effect of Reboxetine on Depression in Parkinson’s Disease Patients

22 How to Select Balance Measures Sensitive to Parkinson’s Disease from Body-Worn Inertial Sensors—Separating the Trees from the Forest

23 Validity of a Fully-Immersive VR-Based Version of the Box and Blocks Test for Upper Limb Function Assessment in Parkinson’s Disease

24 Knowledge, Attitudes, Practices, and Burden During the COVID-19 Pandemic in People with Parkinson’s Disease in Germany

25 Cortical Lewy bodies and Alzheimer-type changes in patients with Parkinson’s disease

26 The Impact of a Novel Immersive Virtual Reality Technology Associated with Serious Games in Parkinson’s Disease Patients on Upper Limb Rehabilitation: A Mixed Methods Intervention Study

27 Apolipoprotein E ε4 allele and progression of cortical Lewy body pathology in Parkinson’s disease

28 Validity of a Fully-Immersive VR-Based Version of the Box and Blocks Test for Upper Limb Function Assessment in Parkinson’s Disease

29 Are there differences in cerebral white matter lesion burdens between Parkinson’s disease patients with or without dementia?

30 Reduced Gray Matter Volume and Risk of Falls in Parkinson’s Disease with Dementia Patients: A Voxel-Based Morphometry Study

31 The Impact of a Novel Immersive Virtual Reality Technology Associated with Serious Games in Parkinson’s Disease Patients on Upper Limb Rehabilitation: A Mixed Methods Intervention Study

32 the association between e326k of gba and the risk of parkinson’s disease

33 5-ht2a receptor binding in the frontal cortex of parkinson’s disease patients and alpha-synuclein overexpressing mice: a postmortem study

34 side of onset in parkinson’s disease and alterations in religiosity: novel behavioral phenotypes

35 increase of eeg spectral theta power indicates higher risk of the development of severe cognitive decline in parkinson’s disease after 3 years

36 therapeutic potential of a prolyl hydroxylase inhibitor fg-4592 for parkinson’s diseases in vitro and in vivo: regulation of redox biology and mitochondrial function

37 evaluation of rna blood biomarkers in the parkinson’s disease biomarkers program

38 serial dopamine transporter imaging of nigrostriatal function in parkinson’s disease with probable rem sleep behavior disorder

39 recent advance in the relationship between excitatory amino acid transporters and parkinson’s disease

40 evidence of oropharyngeal dysfunction in feeding in the rat rotenone model of parkinson’s disease

41 gene therapy for the treatment of parkinson’s disease: the nature of the biologics expands the future indications

42 dopaminergic progenitors derived from epiblast stem cells function similarly to primary vm-derived progenitors when transplanted into a parkinson’s disease model

43 the enzymatic core of the parkinson’s disease-associated protein lrrk2 impairs mitochondrial biogenesis in aging yeast

44 theatre is a valid add-on therapeutic intervention for emotional rehabilitation of parkinson’s disease patients

45 analysis of lrrk2, snca, and itga8 gene variants with sporadic parkinson’s disease susceptibility in chinese han population

46 identification of circulating micrornas for the differential diagnosis of parkinson’s disease and multiple system atrophy.

47 postural stability in parkinson’s disease patients is improved after stochastic resonance therapy

48 the natural history of depression in parkinson’s disease within 30-month follow-up

49 impact of impulse control disorders on sleep-wake regulation in parkinson’s disease

50 the interaction between obstructive sleep apnea and parkinson’s disease: possible mechanisms and implications for cognitive function

51 cranio-caudal kinematic turn signature assessed with inertial systems as a marker of mobility deficits in parkinson’s disease

52 the level of knowledge of parkinson’s disease among nonprofessional caregivers in a movement disorders center in turkey

53 lrrk2 antisense oligonucleotides ameliorate α-synuclein inclusion formation in a parkinson’s disease mouse model

54 serum homocysteine level in parkinson’s disease and its association with duration, cardinal manifestation, and severity of disease

55 clock 3111t/c variant correlates with motor fluctuation and sleep disorders in chinese patients with parkinson’s disease

56 emotional dysfunction in parkinson’s disease

57 gait and tremor assessment for patients with parkinson’s disease using wearable sensors

58 complementary & alternative management of parkinson’s disease: an evidence-based review of eastern influenced practices

59 future scenarios for levodopa-induced dyskinesias in parkinson’s disease

60 abnormal temporal coupling of tactile perception and motor action in parkinson’s disease

61 eye movement control during visual pursuit in parkinson’s disease

62 treatment and rehabilitation in non-motor symptoms of parkinson’s disease

63 parkinson’s disease prevalence and proximity to agricultural cultivated fields

64 identification of nurr1 (exon 4) and foxa1 (exon 3) haplotypes associated with mrna expression levels in peripheral blood lymphocytes of parkinson’s patients in small indian population

65 disrupted nodal and hub organization account for brain network abnormalities in parkinson’s disease

66 can postural instability respond to galvanic vestibular stimulation in patients with parkinson’s disease?

67 p300 wave confirmation in patients with parkinson’s disease

68 cellular and molecular mediators of neuroinflammation in the pathogenesis of parkinson’s disease

69 caenorhabditis elegans: a model to investigate oxidative stress and metal dyshomeostasis in parkinson’s disease

70 Αlpha-synuclein as a mediator in the interplay between aging and parkinson’s disease

71 abdominal massage for the relief of constipation in people with parkinson’s: a qualitative study

72 parkinson’s disease progression: implicit acquisition, cognitive and motor impairments, and medication effects

73 the efficacy and safety of antipsychotic medications in the treatment of psychosis in patients with parkinson’s disease

74 brain-derived neurotrophic factor serum levels correlate with cognitive performance in parkinson’s disease patients with mild cognitive impairment

75 expression analysis of the long non-coding rna antisense to uchl1 (as uchl1) during dopaminergic cells’ differentiation in vitro and in neurochemical models of parkinson’s disease

76 a mouse model of non-motor symptoms in parkinson’s disease: focus on pharmacological interventions targeting affective dysfunctions

77 inflammatory pathways in parkinson’s disease; a bne microarray study

78 quantitative electromyographic analysis of reaction time to external auditory stimuli in drug-naïve parkinson’s disease

79 balance dysfunction in parkinson’s disease: the role of posturography in developing a rehabilitation program

80 postural and intention tremors: detailed clinical study of essential tremor vs. parkinson’s disease

81 diffusion kurtosis imaging of substantia nigra is a sensitive method for early diagnosis and disease evaluation in parkinson’s disease

82 decision and dopaminergic system: an erps study of iowa gambling task in parkinson’s disease

83 a novel microfluidic cell co-culture platform for the study of the molecular mechanisms of parkinson’s disease and other synucleinopathies

84 risc in pd: the impact of micrornas in parkinson’s disease cellular and molecular pathogenesis

85 gender differences in age-related striatal dopamine depletion in parkinson’s disease

86 25-hydroxyvitamin d and severity of parkinson’s disease

87 parkinson’s disease severity at 3 years can be predicted from non-motor symptoms at baseline

88 ventral striatal dopamine synthesis capacity predicts financial extravagance in parkinson’s disease

89 ellagic acid improves hyperalgesia and cognitive deficiency in 6-hydroxidopamine induced rat model of parkinson’s disease

90 need for registration and reporting of acupuncture trials in parkinson’s disease in korea

91 the epidemiology and clinical manifestations of dysexecutive syndrome in parkinson’s disease

92 drosophila mutant model of parkinson’s disease revealed an unexpected olfactory performance: morphofunctional evidences

93 effects of optimized hα-synuclein dna vaccine on cyclooxygenase-2 expression in substantia nigra in a murine model of parkinson’s disease

94 anxiety and depression in parkinson’s disease

95 recurrent falls in people with parkinson’s disease without cognitive impairment: focusing on modifiable risk factors

96 alterations of brain structural network in parkinson’s disease with and without rapid eye movement sleep behavior disorder

97 the use of footstep sounds as rhythmic auditory stimulation for gait rehabilitation in parkinson’s disease: a randomized controlled trial

98 dopamine and the biology of creativity: lessons from parkinson’s disease

99 mindfulness training among individuals with parkinson’s disease: neurobehavioral effects

100 subthalamic nucleus deep brain stimulation in early stage parkinson’s disease is not associated with increased body mass index

101 plasma dna mediate autonomic dysfunctions and white matter injuries in patients with parkinson’s disease

Keyword Connections

Journals

Research Groups

Bibliographies